International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review

References

• Richter T, Nestler-Parr S, Babela R, et al. Rare disease terminology and definitions-a systematic global review: report of the ISPOR rare disease special interest group. Value Health. Internet]. 2015 Sep;18(6):906–914. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26409619
   PubMed Web of Science ®Google Scholar
• Friedmann C, Levy P, Hensel P, et al. Using multi-criteria decision analysis to appraise orphan drugs: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2018 Mar;18(2):135–146.
   PubMed Web of Science ®Google Scholar
• Angelis A, Kanavos P, Montibeller G. Resource allocation and priority setting in health care: a multi-criteria decision analysis problem of value? Glob Policy. 2017;8(March):76–83.
   Google Scholar
• Iskrov G, Stefanov R. Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations. Orphan Drugs Res Rev. 2014;4:1–9.
   Google Scholar
• Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6(1):1–8.
   PubMed Web of Science ®Google Scholar
• Marsh K, Lanitis T, Neasham D, et al. Assessing the value of healthcare interventions using multi-criteria decision analysis: A review of the literature. Pharmacoeconomics. 2014;32(4):345–365.
   PubMed Web of Science ®Google Scholar
• Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making - An introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Heal. 2016;19(1):1–13.
   PubMed Web of Science ®Google Scholar
• Hughes-Wilson W, Palma A, Schuurman A, et al. Paying for the orphan drug system: break or bend? is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74.
   PubMed Web of Science ®Google Scholar
• Naili A. A multi criteria approach for the assessment of drugs for rare diseases. [Internet]. Canada: University of Ottawa; 2016. Available from: https://ruor.uottawa.ca/bitstream/10393/35067/1/Naili_Abdallah_2016_Thesis.pdf
   Google Scholar
• Goetghebeur MM, Wagner M, Samaha D, et al. Exploring values of health technology assessment agencies using reflective multicriteria and rare disease case. Int J Technol Assess Health Care. 2017;33(4):504–520.
   PubMed Web of Science ®Google Scholar
• Schey C, Krabbe PFM, Postma MJ, et al. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs. Orphanet J Rare Dis. 2017;12(1):1–9.
   PubMedGoogle Scholar
• Kolasa K, Zwolinski KM, Kalo Z, et al. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the polish pricing and reimbursement process of orphan drugs. Orphanet J Rare Dis. 2016;11(1):1–12.
   PubMedGoogle Scholar
• Kolasa K, Zwolinski KM, Zah V, et al. Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis. Orphanet J Rare Dis. 2018;13(67):1–14.
   PubMedGoogle Scholar
• Sussex J, Rollet P, Garau M, et al. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Heal. 2013;16(8):1163–1169.
   PubMed Web of Science ®Google Scholar
• Iskrov G. Multi-criteria decision analysis for assessment and appraisal of orphan drugs. Front Public Health. 2016;4(September):1–13.
   PubMedGoogle Scholar
• Wagner M, Khoury H, Willet J, et al. Can the EVIDEM framework tackle issues raised by evaluating treatments for rare diseases : analysis of issues and policies, and context-specific adaptation. Pharmacoeconomics. 2016;34(3):285–301.
   PubMed Web of Science ®Google Scholar
• Gilabert-Perramon A, Torrent-Farnell J, Catalan A, et al. Drug evaluation and decision making in catalonia: development and validation of a methodological framework based on multi-criteria decision analysis (MCDA) for orphan drugs. Int J Technol Assess Health Care. 2017;33(1):111–120.
   PubMed Web of Science ®Google Scholar
• Lockhart CM, Hansen RN. Value assessment of orphan drugs for treatment of rare diseases: a systematic review. Value Heal. [Internet]. 2016 May;19(3):A79. Available from]: https://linkinghub.elsevier.com/retrieve/pii/S1098301516007208
   Web of Science ®Google Scholar
• Gutierrez L, Patris J, Hutchings A, et al. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe. Orphanet J Rare Dis. 2015;10(1):19–22.
   PubMedGoogle Scholar
• Paulden M, Stafinski T, Menon D, et al. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics. 2015;33(3):255–269.
   PubMed Web of Science ®Google Scholar
• Short H, Stafinski T, Menon D. A national approach to reimbursement decision-making on drugs for rare diseases in Canada? Insights from across the Ponds Healthc Policy. 2015;10(4):24–46.
   Google Scholar
• Zelei T, Molnár MJ, Szegedi M, et al. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. Orphanet J Rare Dis. 2016;11(1):1–11.
   PubMedGoogle Scholar
• Winquist E, Bell CM, Clarke JTR, et al. An evaluation framework for funding drugs for rare diseases. Value Heal. 2012;15(6):982–986.
   PubMed Web of Science ®Google Scholar
• EVIDEM. EVIDEM. Concept & definitions, 10th edition [Internet]. 2017 [cited 2019 Jun 16]. Available from: https://www.evidem.org/wp/wp-content/uploads/2017/09/EVIDEM-10th-Edition-Concept-and-definitions.pdf
   Google Scholar
• Goetghebeur MM, Wagner M, Khoury H, et al. Evidence and value: impact on decisionmaking - the EVIDEM framework and potential applications. BMC Health Serv Res. 2008;8:1–16.
   PubMedGoogle Scholar
• Winquist E, Coyle D, Clarke JTR, et al. Application of a policy framework for the public funding of drugs for rare diseases. J Gen Intern Med. 2014 Aug;29(Suppl 3):S774–9.
   PubMedGoogle Scholar
• Marsh K, Ijzerman M, Thokala P, et al. Multiple criteria decision analysis for health care decision making - emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Heal. 2016;19(2):125–137.
   PubMed Web of Science ®Google Scholar
• Kanters TA, Hakkaart L, MPMH R-VM, et al. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug? Expert Rev Pharmacoeconomics Outcomes Res. 2015;15(4):557–559.
   PubMed Web of Science ®Google Scholar
• Mincarone P, Leo CG, Sabina S, et al. Reimbursed price of orphan drugs: current strategies and potential improvements. Public Health Genomics. 2017;20(1):1–8.
   PubMed Web of Science ®Google Scholar
• European Commission, Enterprise and Industry, Pharmaceutical Forum. Final conclusions and recommendations of the pharmaceutical forum: improving access to orphan medicines for all affected EU citizens. European Commission, Ref. Ares(2014)3849337. 2014. p. 1–7.
   Google Scholar
• Garau M, Maignen F, AO’Neill P, et al. Access to orphan drugs in the United Kingdom and other European countries. Int J Technol Assess Health Care. 2017;33(March):64–65.
   Google Scholar
• Kanavos P, Nicod E. What is wrong with orphan drug policies? suggestions for ways forward. Value Heal. 2012;15(8):1182–1184.
   PubMed Web of Science ®Google Scholar
• Devlin N, Sussex J. Incorporating multiple criteria in HTA: methods and Processes. Office of Health Economics, London; 2011.
   Google Scholar
• Nicod E, Kanavos P. Scientific and social value judgments for orphan drugs in health technology assessment. Int J Technol Assess Health Care. 2016;32(4):218–232.
   PubMed Web of Science ®Google Scholar
• Picavet E, Cassiman D, Simoens S. Reimbursement of orphan drugs in Belgium: what (else) matters? Orphanet J Rare Dis. 2014;9(1):1–9.
   PubMedGoogle Scholar